GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds

A new observational study published in JAMA Ophthalmology indicates a potentially elevated risk of neovascular age-related macular degeneration (nAMD) in diabetic patients taking GLP-1 drugs; the study found a 0.2% risk of nAMD in GLP-1 users versus 0.1% in non-users after one year. While the absolute risk remains low, researchers emphasize that the doubling of risk is clinically meaningful, particularly for older adults, and warrants greater awareness and monitoring of visual symptoms in patients on GLP-1s. European regulators have also cited studies showing a doubled risk of nonarteritic anterior ischemic optic neuropathy (NAION) in type 2 diabetics taking semaglutide, the active ingredient in Ozempic and Wegovy.

Analysis

A new observational study published in JAMA Ophthalmology indicates an elevated, albeit low, risk of neovascular age-related macular degeneration (nAMD) among diabetic patients treated with GLP-1 drugs. The research, involving nearly 140,000 Canadian patients with an average age of 66, found that 0.2% of GLP-1 users developed nAMD after one year, compared to 0.1% of non-users, representing a twofold increase in relative risk. While the absolute risk increase is small, study authors highlight its clinical significance, especially for older adults with pre-existing vulnerabilities. This finding adds to a growing list of ocular concerns associated with GLP-1 medications, including reports of abnormal blood vessel growth and retinopathy. Notably, the European Medicines Agency's safety committee recently identified nonarteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect of semaglutide, an active ingredient in prominent GLP-1 drugs like Ozempic and Wegovy, also citing a doubled risk for type 2 diabetics. Researchers speculate potential mechanisms could involve plunging blood glucose levels or direct effects of GLP-1s on retinal receptors, as GLP-1 receptors are present in the retina and the drugs may increase molecules leading to harmful blood vessel formation. The observational nature of the current study means it cannot definitively establish causality, and further research, including animal models and prospective clinical trials, is deemed necessary. Experts advise increased awareness and diligent monitoring of visual symptoms in patients using GLP-1s, rather than immediate changes to prescribing practices, emphasizing that patients should report any new visual disturbances promptly for ophthalmological evaluation. This development warrants attention given the widespread and expanding use of GLP-1 drugs for diabetes and weight management.

Key Decisions for Investors

• Investors should closely monitor ongoing and future research concerning the potential causal link between GLP-1 drugs and ocular adverse events, as confirmed risks could impact the long-term growth trajectory and market perception of this significant drug class.
• Consider the potential for heightened regulatory scrutiny, including possible labeling changes or requirements for enhanced patient monitoring, which could affect manufacturers' costs and the competitive landscape for GLP-1 therapies.
• Evaluate the financial implications for pharmaceutical companies with substantial GLP-1 franchises, including potential litigation exposure and the need for additional R&D to investigate and mitigate these side effects, especially as use expands to broader populations including non-diabetics for weight loss.